A connected biological hypothesis
Chronic inflammation, altered insulin signaling and impaired cellular energy are interrelated processes implicated in multiple diseases of aging. BioVie’s research asks whether carefully modulating these pathways can translate into meaningful clinical outcomes.
This remains a research hypothesis. Clinical trials are required to determine whether BioVie’s investigational candidates are safe and effective.
Bezisterim
Neuroscience
Bezisterim (NE3107) is an orally administered, blood-brain-barrier-permeable small molecule being studied in Parkinson’s disease and Long COVID, with prior clinical research in Alzheimer’s disease.
Preclinical and clinical research has examined ERK and NF-κB signaling, inflammatory mediators including TNF-α, insulin sensitivity, cognition, movement and biological-age-associated epigenetic markers.
BIV201
Hepatology
BIV201 is an investigational continuous-infusion formulation of terlipressin designed for use with a portable pump. It is being developed for refractory ascites associated with liver cirrhosis.
The research rationale centers on vascular tone, portal pressure, renal and hepatic blood flow, and the physiological systems involved in fluid accumulation.
Evidence standards
BioVie communicates study design, development stage and source material alongside scientific hypotheses. Conference posters and company analyses can inform future research, but they do not replace confirmatory, adequately controlled studies or regulatory review.
Development-stage information can change. Investigational candidates are not approved, and safety and efficacy have not been established. Review source documents and current regulatory disclosures.